Satavaptan

Satavaptan

Satavaptan

Chemical compound


Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist[1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites.[2] Development was discontinued in 2009.[3]

Quick Facts Clinical data, ATC code ...

References

  1. Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clinical Journal of the American Society of Nephrology. 1 (6): 1154–60. doi:10.2215/CJN.00160106. PMID 17699341.
  2. "Satavaptan". Adis Insight. Springer Nature Switzerland AG.

Share this article:

This article uses material from the Wikipedia article Satavaptan, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.